Cargando…

A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer

Pembrolizumab monotherapy or combination therapy is an approved treatment for various advanced non-small cell lung cancer (NSCLC) indications. We review published cost-effectiveness analyses (CEAs) of pembrolizumab as treatment for NSCLC and provide in-depth assessment of their methodologies. Fourte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiao, Nan, Insinga, Ralph, de Lima Lopes Junior, Gilberto, Cook, John, Sénécal, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333166/ https://www.ncbi.nlm.nih.gov/pubmed/33469803 http://dx.doi.org/10.1007/s41669-020-00255-2

Ejemplares similares

Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective
por: Qiao, Nan, et al.
Publicado: (2021)

Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden
por: Criss, Steven D., et al.
Publicado: (2020)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
por: Sehgal, Kartik, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
por: Zhang, Xin, et al.
Publicado: (2023)

Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
por: Tan, Pui San, et al.
Publicado: (2017)

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2021)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab for the treatment of Non–Small-Cell lung cancer: A systematic review
por: Zhang, Chuan, et al.
Publicado: (2022)

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
por: Gower, Arjan, et al.
Publicado: (2022)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease
por: Fujita, Tetsuo, et al.
Publicado: (2020)

Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
por: Shi, Yafei, et al.
Publicado: (2021)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic
por: Moffat, Gordon Taylor, et al.
Publicado: (2023)

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
por: Isla, Dolores, et al.
Publicado: (2023)

Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer
por: Monirul, Sanjana, et al.
Publicado: (2020)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
por: Sehgal, Kartik, et al.
Publicado: (2021)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
por: Halmos, Balazs, et al.
Publicado: (2020)

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2019)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma
por: Oki, Rikako, et al.
Publicado: (2019)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg, Frank, et al.
Publicado: (2019)

Advanced G‐CSF‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy
por: Matsui, Yohei, et al.
Publicado: (2020)

Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer
por: Fujii, Hironori, et al.
Publicado: (2022)

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
por: Sonehara, Kei, et al.
Publicado: (2021)

A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
por: Wu, Kai, et al.
Publicado: (2022)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
por: Kaira, Kyoichi, et al.
Publicado: (2023)

Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
por: Jiménez Galán, Rocío, et al.
Publicado: (2023)

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
por: Gullapalli, Sneha, et al.
Publicado: (2020)

Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

A Fatal Case of Pembrolizumab-Induced Myocarditis in Non–Small Cell Lung Cancer
por: Cohen, Max, et al.
Publicado: (2020)

Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer
por: Baroz, Angel R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_klu878enrh2b5df5lmsus3l8ok